Clinical Trials on KRAS G12C Mutation in Hong Kong
Total 36 results
-
AmgenActive, not recruitingAdvanced/Metastatic Solid Tumors With KRAS p.G12C MutationTaiwan, Hong Kong
-
The University of Hong KongUnknownAML | FLT3-ITD MutationHong Kong
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
The Hong Kong Polytechnic UniversityEnrolling by invitationAmputation | Prosthesis UserHong Kong
-
The University of Hong KongCompletedAML | FLT3-ITD MutationHong Kong
-
The University of Hong KongUnknownNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIBHong Kong
-
The University of Hong KongRecruitingRecurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH MutationHong Kong
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
Chinese University of Hong KongCompletedAmputation | Diabetic Foot UlcerChina
-
The University of Hong KongNorth District Hospital; Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole... and other collaboratorsUnknownSelf Inflicted Injury | Suicide and Self Inflicted InjuryHong Kong
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
D3 Bio (Wuxi) Co., LtdRecruitingKRAS P.G12CAustralia, Korea, Republic of, China, United States, Hong Kong
-
Southern California Institute for Research and...California State University, Long Beach; California State University, Dominguez...UnknownTranstibial AmputationUnited States
-
Southern California Institute for Research and...CompletedUnilateral Transfemoral AmputationUnited States
-
Southern California Institute for Research and...Vanderbilt UniversityUnknownAmputation | Energy Expenditure | Artificial Limbs | KineticsUnited States
-
Symphogen A/SCompletedNSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene AmplificationUnited States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, ColorectalUnited States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
-
ETOP IBCSG Partners FoundationAstraZenecaActive, not recruitingNSCLC Stage IV | EGFR Gene MutationSingapore, Sweden, Korea, Republic of, Spain, Switzerland, Netherlands, Italy, Poland
-
Cullinan Therapeutics Inc.RecruitingNon Small Cell Lung Cancer | EGFR Exon 20 MutationUnited States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
BayerRecruitingAdvanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 MutationHong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
-
PfizerCompletedNon-small Cell Lung Cancer With EGFR-Activating MutationsItaly, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Recursion Pharmaceuticals Inc.RecruitingSolid Tumor | APC Gene Mutation | AXIN1 Gene MutationUnited States
-
VA Office of Research and DevelopmentRecruitingDiabetes | Amputation | OsteomyelitisUnited States
-
Vertex Pharmaceuticals IncorporatedCompletedCystic Fibrosis, Homozygous for the F508del CFTR MutationUnited States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
-
Vertex Pharmaceuticals IncorporatedCompletedCystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationUnited States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditionsUnited States
-
ArriVent BioPharma, Inc.Allist Pharmaceuticals, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 MutationsUnited States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
-
Seagen Inc.Active, not recruitingUrologic Neoplasms | Uterine Cervical Neoplasms | Uterine Neoplasms | Carcinoma, Non-Small-Cell Lung | Biliary Tract Neoplasms | HER2 Mutations Breast NeoplasmsUnited States, United Kingdom, Spain, Korea, Republic of, Italy, Belgium, Germany, Japan, Netherlands, Poland